12:00 AM
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabozantinib: Phase II data

A single-arm, open-label, U.S. Phase II trial in 37 patients with EGFR mutation-positive NSCLC that progressed following an EGFR tyrosine kinase inhibitor (TKI) therapy showed that once-daily 40 mg oral cabozantinib plus Tarceva erlotinib led to 4 partial responses. Additionally, 20 of 23 evaluable patients had a >=30% increase in tumor doubling time. The most common grade 3 adverse event was diarrhea and 2 patients had grade 3 maculopapular rash. Grade 4 adverse events included vomiting, elevated lipase and elevated amylase. The trial was sponsored by the NCI. Data were presented at the...

Read the full 474 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >